Financial Performance - Operating revenue for Q1 2024 was CNY 25,100,709.69, representing a 14.13% decrease compared to CNY 29,231,472.90 in Q1 2023[11] - Net profit attributable to shareholders for Q1 2024 was a loss of CNY 4,450,874.05, a 48.02% decline from a loss of CNY 3,006,966.31 in the same period last year[11] - Total operating revenue for Q1 2024 was ¥25,100,709.69, a decrease of 14.5% compared to ¥29,231,472.90 in Q1 2023[36] - Net loss for Q1 2024 was ¥4,450,874.05, compared to a net loss of ¥3,006,966.31 in Q1 2023, representing an increase in loss of 48.2%[37] - Operating profit for Q1 2024 was -¥4,450,874.50, compared to -¥2,996,882.87 in Q1 2023, indicating a worsening of 48.6%[37] Cash Flow - The net cash flow from operating activities for Q1 2024 was a negative CNY 757,836.73, a 90.09% improvement from a negative CNY 7,646,015.20 in Q1 2023[11] - In Q1 2024, the cash inflow from operating activities was CNY 31,482,031.79, a decrease of 15.4% compared to CNY 37,289,256.27 in Q1 2023[42] - The net cash outflow from operating activities was CNY -757,836.73, significantly improved from CNY -7,646,015.20 in the same period last year[42] - Cash outflow for purchasing goods and services was CNY 20,049,683.00, down from CNY 24,093,173.12 in Q1 2023, reflecting a 16.9% reduction[42] - The net cash flow from investing activities was CNY -3,791,310.00, compared to CNY -16,552,276.64 in Q1 2023, indicating a 77% improvement[43] Assets and Liabilities - Total assets as of March 31, 2024, reached CNY 426,032,623, a 0.55% increase from CNY 423,712,742.87 at the end of 2023[11] - The company's total liabilities to assets ratio (consolidated) was 26.56% as of March 31, 2024, compared to 25.11% at the end of 2023[11] - Total liabilities rose to CNY 112,888,257.61, compared to CNY 106,148,658.77, marking an increase of about 6.9%[34] - Current liabilities totaled CNY 87,477,841.92, up from CNY 79,884,493.06, representing an increase of approximately 9.9%[34] - Non-current liabilities decreased slightly to CNY 25,410,415.69 from CNY 26,264,165.71, a decline of about 3.3%[34] Shareholder Information - The total number of ordinary shareholders was 5,168 as of the end of the reporting period[17] - The largest shareholder, Yan Heping, holds 53,246,000 shares, representing 47.81% of total shares[20] - The total shares held by the top ten shareholders amount to 79,632,188, which is 71.51% of the total shares[20] Expenses - Research and development expenses for Q1 2024 were ¥2,226,327.07, slightly down from ¥2,464,389.29 in Q1 2023, a decrease of 9.7%[36] - Sales expenses for Q1 2024 were ¥3,227,327.55, down 18.2% from ¥3,946,838.44 in Q1 2023[36] - Management expenses increased to ¥5,563,313.76 in Q1 2024, up 20.0% from ¥4,636,128.14 in Q1 2023[36] Other Financial Metrics - Non-recurring gains and losses for Q1 2024 totaled CNY 1,239,689.21, with a net amount after tax of CNY 1,228,366.31[14] - Basic and diluted earnings per share for Q1 2024 were both -¥0.04, compared to -¥0.05 in Q1 2023[38] - Credit impairment losses for Q1 2024 were -¥17,948.13, compared to a gain of ¥246,158.06 in Q1 2023, indicating a significant decline[37]
大禹生物(871970) - 2024 Q1 - 季度财报